AstraZeneca CEO Expects Interim Results from Paused Coronavirus Vaccine Trial Before End of 2020
Progress on AstraZeneca's (NYSE: AZN) coronavirus vaccine candidate took a breather this week after an adverse health event triggered a pause in enrollment at trial sites around the globe. Despite the setback, on Wednesday afternoon, CEO Pascal Soriot told analysts he still expects interim results from multiple phase 3 studies of the candidate before the end of the year if those trials are allowed to continue soon.
On Tuesday, AstraZeneca issued statements describing a partial hold on phase 3 trials of AZD1222. The company is among the front-runners in the race to develop vaccines that safely teach our immune systems to recognize and attack SARS-CoV-2, the coronavirus that causes COVID-19, before it gains a foothold in the body.
Image source: Getty Images.
Source Fool.com
